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  35 
ABSTRACT  36 
Dexamethasone (dex) treatment of F0 pregnant rodents alters F1 placental function and adult 37 
cardiometabolic phenotype. The adult phenotype is transmitted to the F2 generation without 38 
further intervention but whether F2 placental function is altered by F0 dex treatment remains 39 
unknown. In this study, F0 mice were untreated or received dex (0.2 µg g
-1
day
-1
 s.c.) over 40 
days (D) 11-15 or D14-18 of pregnancy (term D21). Depending on the period of F0 dex 41 
treatment, F1 offspring were lighter at birth or grew more slowly until weaning (P<0.05). 42 
Glucose tolerance (1g kg
-1
 ip) of adult F1 males was abnormal. Mating F1 males dex exposed 43 
prenatally with untreated females had no effect on F2 placental function on D19 of 44 
pregnancy. Contrastingly, when F1 females were mated with untreated males, F2 placental 45 
clearance of the amino acid analogue, 
14
C-methylaminoisobutyric acid, was increased by 46 
75% at D19 specifically in dams prenatally dex exposed at D14-18 (P<0.05). Maternal 47 
plasma corticosterone was also increased but F2 placental Slc38a4 expression was decreased 48 
in these dams (P<0.05). F0 dex treatment had no effect on F2 fetal or placental weights 49 
irrespective of lineage. Effects of F0 dex exposure are, therefore, transmitted 50 
intergenerationally to the F2 placenta via the maternal but not paternal line. 51 
  52 
INTRODUCTION 53 
Antenatal treatment with the synthetic glucocorticoid, dexamethasone (dex) is used clinically 54 
to induce fetal maturation in women threatened with preterm delivery. Despite the benefits to 55 
neonatal survival, antenatal dex exposure is associated with reduced size at birth, especially 56 
when glucocorticoid dosage is repeated or inappropriately timed (Khan et al. 2011). In turn, 57 
low birth weight leads to increased cardiometabolic disease risk in later life (Barker 1994). 58 
When dex is given to (F0) pregnant rodents, fetal and placental growth is restricted (Smith 59 
2003; Ain 2005; Baisden et al. 2007; Cuffe et al. 2011; Xu et al. 2011; Vaughan et al. 2013) 60 
and the offspring (F1) develop high blood pressure, hyperglycaemia and insulin resistance 61 
(Benediktsson et al. 1993; Nyirenda et al. 1998; Sugden et al. 2001; O'Sullivan et al. 2013). 62 
More recent animal studies have demonstrated that the phenotype programmed in the F1 63 
offspring by prenatal glucocorticoid overexposure can be transmitted to their offspring (F2), 64 
via either the mother or father, in the absence of further treatment (Drake et al. 2005; Crudo 65 
et al. 2012; Iqbal et al. 2012; Long et al. 2013a; Long et al. 2013b; Radford et al. 2014). 66 
Depending on whether it is transmitted through the male or female line, passage of F1 67 
phenotypic traits to the F2 and subsequent generations may be a consequence of germ-line 68 
independent changes in maternal intrauterine environment or stable epigenetic changes to the 69 
chromatin inherited at fertilisation (Radford and Ferguson-Smith 2011). As the placenta is 70 
both zygote-derived and in direct contact with the maternal environment, changes in placental 71 
phenotype may mediate the physiological effects of grandparental environmental insults on 72 
the F2 fetus. 73 
 74 
In the F1 generation, placental structure is altered as a direct consequence of dex treatment of 75 
the F0 pregnant mother (Hahn et al. 1999; Hewitt et al. 2006; Cuffe et al. 2011; O'Connell et 76 
al. 2013; Vaughan et al. 2013). Often, dex causes a reduction in the proportion of the 77 
labyrinthine zone (Lz) responsible for materno-fetal exchange, along with changes in the size 78 
and density of Lz blood vessels (Hewitt et al. 2006; O'Connell et al. 2011; Vaughan et al. 79 
2013). Amino acid transport by the F1 placenta is also altered near term in pregnant mice 80 
given dex orally or by injection (Audette et al. 2011; Vaughan et al. 2013). In the F2 progeny 81 
of F1 rats exposed to dex in utero, there is altered placental expression of genes including the 82 
amino acid transporter genes, along with parent of origin-specific changes in feto-placental 83 
growth (Drake et al. 2011). Similarly, F1 prenatal exposure to nutritional manipulations that 84 
are known to raise endogenous glucocorticoid concentration, alters expression of nutrient 85 
transporters in the F2 mouse placenta (Isganaitis et al. 2011; Radford et al. 2012). However, 86 
whether there are structural and functional changes in the actual nutrient transport capacity of 87 
the F2 placenta as a result of dex treatment of the pregnant grandmother remains unknown. 88 
 89 
Therefore, this study quantified F2 placental clearance of the non-metabolisable amino acid 90 
analogue, 14C-methylaminoisobutyric acid (MeAIB), and the volume of the placental Lz and 91 
junctional zone (Jz) in pregnant mice that were either exposed prenatally to dex and mated to 92 
untreated males or were untreated themselves and mated with males exposed to dex in utero. 93 
The System A/SNAT family of transporters that transfer MeAIB across the placenta are 94 
known to be essential for normal fetal growth (Cramer et al. 2002). Dex was administered to 95 
F0 dams at a dose similar to that given to pregnant women threatened with preterm delivery 96 
(Brownfoot et al. 2008). When given to pregnant animals in previous studies, this dex dosage 97 
is known to program abnormal cardiometabolic phenotype in the first-generation offspring 98 
(Benediktsson et al. 1993; Dodic et al. 1998; Nyirenda et al. 1998; Woods and Weeks 2005; 99 
de Vries et al. 2007). F0 females were injected with dex either over the period of maximal 100 
placental or fetal growth (Coan et al. 2004), whilst controls were untreated in order to remove 101 
the known stress of injection per se (Meijer et al. 2006; Drude et al. 2011; Vaughan et al. 102 
2013). The study was designed to test the hypothesis that F2 placental phenotype would 103 
depend on the timing of F0 dex treatment and on whether treatment was of the maternal or 104 
paternal grandmother.  105 
Methods 106 
Animals 107 
All procedures were conducted under the Animals (Scientific Procedures) Act 1986 by UK 108 
Home Office license holders. C57BL6/J mice (Harlan, UK) were housed in 12hr:12hr 109 
dark:light conditions with ad libitum access to food and water throughout. Sixteen female 110 
mice were mated with stud males and the day of copulatory plug detection designated as day 111 
(D) 1 of pregnancy. Pregnant females (F0) were given a subcutaneous injection of dex (0.2 112 
µg g
-1
 day
-1
 in 0.2 ml sterile saline vehicle) on the morning of each of five days, from D11 to 113 
D15 (n=6) or from D14 to D18 (n=5). Control females (n=5) were left untreated.  Females 114 
were allowed to litter normally at term and to suckle their own offspring. Neonates (F1) were 115 
weighed and sexed, and litter size reduced to four, balanced by sex where possible. Pups were 116 
weaned at three weeks of age, ear-notched for identification then housed in groups of the 117 
same sex but from mixed litters and maternal treatment groups. Body weight was recorded 118 
weekly before and after weaning. Upon reaching maturity, 6-8 week old F1 females (control 119 
n=7; D11-15 dex n=6, D14-18 dex n=6) were mated with stud males. Twelve to fourteen 120 
week old F1 male mice (control n=7, D11-15 dex n=9, D14-18 dex n=14) were mated with 121 
virgin untreated females, which received no further treatment during pregnancy (control 122 
n=10, D11-15 dex n=13, D14-18 dex n=18). Between 1 and 3 pregnancies were successfully 123 
sired by each F1 male.  124 
 125 
Glucose tolerance test 126 
After mating, a glucose tolerance test (1 g kg
-1
, 10% w/v in sterile saline i.p.) was carried out 127 
on the F1 males after an overnight fast at 14 weeks of age. Glucose concentrations were 128 
measured before and at 15, 30, 45, 60, 90 and 120 minutes after glucose injection in a small 129 
quantity of blood taken from the tail vein (OneTouch glucometer, Orthoclinical Diagnostics). 130 
Two weeks later, males were anaesthetized (fentanyl-fluanisone:midazolam:water, 1:1:2, 131 
10µl g
-1
 body weight) and a blood sample collected for corticosterone measurement (ELISA, 132 
IBL International, Hamburg, Germany) before euthanasia by cervical dislocation for tissue 133 
collection. 134 
 135 
F2 placental phenotype 136 
Pregnant F1 females, and untreated females mated with F1 males were anaesthetized on D19 137 
of pregnancy and unidirectional materno-fetal clearance of 14C-methylaminoisobutyric acid 138 
(100µl, NEN NEC-671, specific activity 1.86 GBq mmol
-1
) determined as described 139 
previously (Vaughan et al. 2012). A cardiac blood sample was taken up to 4 minutes after 140 
injection of the tracer and the mother was killed by cervical dislocation. Plasma was 141 
separated by centrifugation for liquid scintillation counting and corticosterone measurement. 142 
The gravid uterus was removed and individual fetuses and placentae dissected and weighed. 143 
Fetuses were lysed (5ml Biosol, National Diagnostics, UK at 55°C) for liquid scintillation 144 
counting. The placenta closest in weight to the mean of each litter was halved and fixed in 145 
formaldehyde (4% in 0.1M HEPES) for histological processing and stereological 146 
determination of volumes of the Lz and Jz, responsible for the transport and endocrine 147 
functions of the placenta (Vaughan et al. 2012). The placenta second closest to the mean was 148 
snap frozen in liquid nitrogen for later gene expression analysis. Expression of System A 149 
amino acid transporter isoforms, Slc38a1, Slc38a2 and Slc38a4, was determined relative to 150 
Hprt1 and Gapdh using quantitative RT-PCR and the ΔΔCt method (Vaughan et al. 2012). 151 
 152 
Statistics 153 
All data are mean ± SEM. F1 glucose tolerance was assessed by repeated-measures two-way 154 
ANOVA, with F0 treatment and time from glucose injection as independent factors. The 155 
effect of F0 treatment on all other measured variables was determined by one-way ANOVA 156 
with Bonferroni post-hoc test. Linear correlations of the measured variables were computed 157 
by Pearson’s product-moment coefficient. 158 
  159 
Results 160 
F1 neonatal weight and postnatal growth 161 
All F0 females littered on D21 of pregnancy. Litter size was similar in all treatment groups 162 
(average 6.6 pups, range 4-8 pups); however, there was a significant effect of F0 dex 163 
treatment on F1 birth weight (Table 1). Newborn control and D11-15 dex treated pups were 164 
similar in weight whereas those exposed to dex from D14 to D18 were 8% lighter (Table 1).  165 
Conversely, during suckling, D11-15 dex pups gained weight more slowly (fractional growth 166 
rate, P<0.05 for males and females combined) such that by weaning at 3 weeks of age both 167 
males and females were lighter than controls and D14-18 dex pups (Table 1). Although both 168 
groups of dex offspring grew faster than controls after weaning (P<0.05), D11-15 dex treated 169 
animals remained lightest at week 6, when the females were mated (Table 1).  170 
 171 
F1 male lineage 172 
At 14 weeks of age, body weight was similar in the three groups of F1 males (control 30.3 ± 173 
1.1, dex D11-15 30.7 ± 0.7, dex D14-18 31.0 ± 0.7 g, P>0.05). After glucose administration, 174 
the maximum increment in blood glucose concentration from baseline values was 175 
significantly less in both dex exposed groups than in the controls (Fig. 1). Moreover, blood 176 
glucose concentration remained elevated above baseline for longer in dex males (Fig. 1, 177 
P<0.05, one sample t-test of 120 min glucose versus zero), than in the controls (P>0.05). 178 
However, neither the area under the curve of blood glucose with time (Fig. 1) nor the basal 179 
fasting glucose concentrations differed with F0 treatment (control 6.9 ± 0.4, dex D11-15 7.4 180 
± 0.4, dex D14-18 8.2 ± 0.4 mM, P>0.05) . There was also no significant effect of F0 181 
treatment on F1 plasma corticosterone concentrations at 16 weeks of age (control 233 ± 34, 182 
dex D11-15 170 ± 15, dex D14-18 189 ± 9 ng ml
-1
). Heart weight was significantly greater in 183 
D14-18 dex treated males compared to the other two groups, both as a percentage of total 184 
body weight and an absolute value (control 142 ± 2, dex D11-15 144 ± 7, dex D14-18 159 ± 185 
4 mg, P<0.05). 186 
 187 
When F1 adult males were mated with untreated females, neither maternal weight nor F2 188 
fetal and placental weights differed between the three groups at D19 of pregnancy (Table 2). 189 
Materno-fetal clearance of MeAIB across the F2 placenta and placental expression of the 190 
Slc38a genes were also similar in control and dex groups (Figure 2A and B). The Lz and Jz 191 
volumes of the F2 placentae, determined by stereology, did not differ with paternal prenatal 192 
treatment (Table 2). Neither did plasma corticosterone concentrations of the D19 pregnant 193 
females differ with paternity of their offspring (control 603 ± 64 ng/ml, D11-15 dex 540 ± 42 194 
ng/ml, D14-18 dex 687 ± 93 ng ml
-1
, P>0.05).  195 
 196 
F1 female lineage 197 
Body weight of the F1 females at D19 of their pregnancy differed with F0 treatment: those 198 
exposed prenatally to dex from D11 to 15 were lightest whereas the controls were heaviest 199 
(Table 2). In particular, the weight of the gravid uterus was less in F1 dams exposed to dex 200 
prenatally at D11-15 than in the other two groups. However, F2 litter size and fetal and 201 
placental weights were unaffected by the treatment of their maternal grandmother (Table 2). 202 
Clearance of MeAIB across the F2 placenta was 75% greater in F1 dams exposed prenatally 203 
to dex at D14-18, compared to the other two groups (Figure 2C). In contrast, expression of 204 
Slc38a4, but not Slc38a1 or Slc38a2, was significantly lower in the F2 placentae of the F1 205 
mothers dex exposed at D14-18 , compared to the control group (Fig 2D). At D19 of 206 
pregnancy, plasma corticosterone concentrations were elevated above control values (644 ± 207 
48 ng ml
-1
, n = 5) in F1 dams exposed prenatally to dex at D14-18 (1119 ± 131 ng ml
1
, n = 6, 208 
P<0.05) but not at D11-15 dams (600 ± 38 ng ml
-1
, n = 5, P>0.05).  The volumes of the Lz 209 
and Jz in the F2 placenta were similar in the three groups of F1 dams (Table 2). 210 
  211 
DISCUSSION 212 
This study is the first to demonstrate altered function of the F2 mouse placenta as a 213 
consequence of treating F0 pregnant dams with the synthetic glucocorticoid, dexamethasone. 214 
F1 neonates of F0 dams treated with dex close to term were growth restricted at birth but 215 
subsequently caught up in weight with controls whereas those exposed to dex earlier in 216 
gestation had normal birth weights but grew poorly in the period immediately after birth. 217 
Irrespective of the timing of F0 dex treatment, male F1 offspring had abnormal glucose 218 
tolerance as adults. However, prenatal dex exposure of the F1 males had no effect on F2 fetal 219 
weight or placental phenotype. In contrast, prenatal dex exposure of F1 females led to an 220 
increase in F2 placental MeAIB transport that was specific to the grandprogeny of F0 dams 221 
treated with dex near to term. 222 
 223 
Previously, dex treatment either from D11 to D15 or from D14 to D18 of mouse pregnancy 224 
has been shown to reduce fetal and placental weight at D19 (Vaughan et al. 2013). However, 225 
in the current study growth restriction was only seen at birth in the F1 neonates prenatally 226 
exposed to dex over the later of these two periods of F0 treatment. This indicates that 227 
compensatory increases in fetal growth can occur during late gestation in mice but only when 228 
there are more than 2 days between the end of the insult and birth. The growth restricted F1 229 
neonates exposed to dex from D14-18 did attain normal weight by 3 weeks after birth, 230 
consistent with the catch-up growth reported in human infants of low birth weight  (Morrison 231 
et al. 2010).  In contrast, growth of the F1 neonates exposed to dex from D11-15 was slow 232 
after birth so that they were lighter than the other two groups at weaning and remained so for 233 
the rest of the experiment, despite a normal birth weight. This may be a consequence of 234 
reduced absorption of nutrients from the neonatal gut, or changes in the composition or 235 
volume of milk produced by the dams during lactation (Drozdowski et al. 2009). Placental 236 
production of lactogenic hormones may have been impaired by dex administration as the dex 237 
exposed placenta is known to weigh less at the end of treatment and remain small at D19 238 
after treatment from D11-15 (Vaughan et al. 2013). Indeed, the higher growth rate seen in 239 
both groups of dex exposed F1 offspring relative to the controls after weaning suggests that 240 
there is a degree of growth constraint during the period of suckling after dex treatment of 241 
their mothers (Vaughan et al. 2013). With group-housed animals, food intake of the F1 242 
offspring could not be determined in the current study so nothing is known about the 243 
potential contribution of glucocorticoid programmed changes in appetite to postnatal growth 244 
(Moisiadis and Matthews 2014; Ross and Desai 2014). 245 
 246 
In common with the adult offspring of rats treated with dexamethasone in late pregnancy 247 
(Lindsay et al. 1996a; Lindsay et al. 1996b; Nyirenda et al. 1998; Woods and Weeks 2005; 248 
Franko et al. 2010) adult F1 male mice of F0 dex treated dams had abnormal glucose 249 
tolerance in the current study with a glucose increment that was smaller initially but more 250 
prolonged than seen in the control animals. Reduced maximum blood glucose increment may 251 
suggest improved glucose tolerance and is consistent with the faster post-weaning weight 252 
gain of the dex exposed F1 animals. However, increased glucose uptake in the juvenile 253 
animals may lead to greater fat deposition and eventually insulin resistance in old age 254 
(Nyirenda et al. 1998). Alternatively, the smaller rise in blood glucose level in 255 
dexamethasone exposed F1 male mice may be due to impaired absorption of the glucose 256 
injected intraperitoneally. The increases in heart weight in these F1 males also suggests that 257 
there are changes in adult cardiovascular function as a result of prenatal dex exposure, as seen 258 
in other species (Woods and Weeks 2005). Maternal dex treatment during pregnancy has also 259 
been shown to alter the response of the hypothalamic-pituitary-adrenal (HPA) axis to stress in 260 
the adult offspring in rats and other species (Shoener et al. 2006; Hauser et al. 2009; Iqbal et 261 
al. 2012; Long et al. 2013a). However, there was little evidence of programmed changes in 262 
adrenocortical secretion in the F1 dex exposed adult males studied here, as plasma 263 
corticosterone concentration did not differ with F0 treatment. Other than body weight, no 264 
phenotypic data was collected on non-pregnant F1 female mice in the present study as all 265 
were mated in order to create the F2 generation. Metabolic phenotyping of these females, for 266 
example by measuring glucose tolerance, either before or during pregnancy may also have 267 
confounded the F2 outcomes by introducing additional stresses. 268 
 269 
There were no differences in feto-placental weight, placental MeAIB clearance or placental 270 
structure between F2 litters of control and F1 dex-exposed male mice. Previous studies in rats 271 
have shown inheritance of metabolic traits to F2 adults via the male offspring of F0 dams 272 
treated with a similar dose of dex in late pregnancy (Drake et al. 2005). These changes 273 
associated with a small decrease in F2 placental weight at day 20 of pregnancy (Drake et al. 274 
2011).  However, the present data do not support a major role for the placenta in transmitting 275 
a dex programmed F1 phenotype to the F2 generation patrilinearly in mice. Alternative 276 
mechanisms, for example epigenetic changes in imprinted or other genes more influential in 277 
post-natal growth and glucose tolerance than placental phenotype, may result in germ-line 278 
dependent paternal intergenerational inheritance, as occurs following undernutrition of F0 279 
pregnant mice (Radford et al. 2014). 280 
 281 
When F1 female offspring were bred with control males, there was a reduction in the weight 282 
of the entire gravid uterus specifically in those dams exposed to dex between D11 to D15 of 283 
their intrauterine development. As F1 females from this group were lighter than controls at 284 
weaning, and tended to remain so at mating, there may have been a greater degree of 285 
maternal constraint on expansion of the uterus and its contents during pregnancy, despite no 286 
significant differences in weights of the individual F2 fetuses and placentae. F1 dams given 287 
dex prenatally from D14 to D18 of gestation had raised plasma corticosterone and greater 288 
materno-fetal MeAIB clearance, a measure of F2 placental System A amino acid transport 289 
capacity, on D19 of their own pregnancy. In common with our previous findings (Vaughan et 290 
al. 2012; Vaughan et al. 2013), increased System A activity was not explained by changes in 291 
gene expression of Slc38a transporters. Indeed, F2 placental expression of the imprinted 292 
Slc38a4 gene was reduced significantly in D14-18 dams that had the highest F2 placental 293 
MeAIB clearance. In contrast, Slc38a4 expression is increased in the F2 rat placenta after 294 
exposure of the F1 mother to dex prenatally in late gestation (Drake et al. 2011) but its 295 
expression is unaltered in the F2 placenta following F1 prenatal undernutrition in mice 296 
(Radford et al. 2012). Species differences in the effects of F0 manipulations on F2 placental 297 
Slc38a4 abundance may reflect yet unidentified morphological changes in the placenta or 298 
promoter-specific regulation of the various Slc38a4 transcripts in the present and previous 299 
studies (Constancia et al. 2005). 300 
 301 
In the present study, the F1 pregnant dams with the greatest placental capacity for System A 302 
amino acid transport had the highest maternal corticosterone concentrations.  In previous 303 
studies, placental MeAIB clearance was reduced when corticosterone was given directly to 304 
pregnant mice for several days in late gestation (Vaughan et al., 2012). The high 305 
corticosterone concentration observed in the pregnant F1 dam exposed prenatally to dex from 306 
D14-18 may, therefore, be due to an elevated but transient HPA response to the acute stress 307 
of handling and terminal anaesthesia in line with the enhanced HPA responsiveness seen in 308 
adult offspring of other species after prenatal exposure to dex (Liu et al. 2001; Shoener et al. 309 
2006). Alternatively, since transplacental transfer of fetal corticosterone can contribute to 310 
maternal levels during mouse pregnancy (Barlow et al. 1974; Montano et al. 1993; Cottrell et 311 
al. 2012), the high maternal corticosterone levels may reflect enhanced HPA activity of the 312 
F2 fetuses.  Certainly, intergenerational transmission of an altered HPA phenotype is seen in 313 
other species after F0 dex treatment (Long et al. 2013a; Moisiadis and Matthews 2014). The 314 
high corticosterone concentration observed in the pregnant F1 dam exposed prenatally to dex 315 
from D14-18 may, therefore, be the consequence rather than the cause of the changes in F2 316 
placental function.  Programmed adaptations in F1 maternal glucose metabolism may also 317 
contribute to the changes in F2 placental function, since prenatal dex exposure is known to 318 
alter adult glucose tolerance in F1 females in large animals (Long et al. 2012) and in F1 319 
males in the present study. 320 
 321 
The mechanism by which F0 dex treatment during mouse pregnancy leads to enhanced amino 322 
acid transport of the F2 placenta via the maternal lineage, therefore, remains unclear. It may 323 
involve changes in the chromatin, cytoplasm or mitochondria of the oocyte induced during 324 
either oogenesis in the F0 dam or folliculogenesis in the F1 mother as seen after 325 
periconceptional dietary manipulations of F0 mouse dams (Watkins et al. 2008; Igosheva et 326 
al. 2010; Lager et al. 2014). Alternatively, increased F1 maternal constraint associated with 327 
her poor postnatal growth or programmed changes in the F2 fetus may lead to an increased 328 
fetal demand for nutrients, which then results in an increased placental nutrient supply.  329 
Enhanced placental amino acid transport has been observed previously in response to fetal 330 
demand signals when mismatches between the fetal drive for growth and the placental 331 
nutrient supply are induced either nutritionally or genetically (Vaughan et al., 2012). In turn, 332 
an altered placental phenotype may influence the maternal metabolic profile by changing the 333 
maternal endocrine environment and resource allocation between the mother and her 334 
offspring with consequences for subsequent pregnancies and the reproductive performance of 335 
the next generations (Fowden and Moore 2012). 336 
 337 
In summary, the effects of F0 dex treatment on F2 placental phenotype depend on the period 338 
of F0 treatment and whether the F1 mother or father was overexposed in utero. Changes in 339 
the F2 placental capacity for amino acid transport were only seen with F0 treatment close to 340 
term transmitted via the maternal lineage, even though there were changes in growth in both 341 
sexes and metabolic alterations in the F1 males. Taken together, these observations suggest 342 
that the placenta can contribute to intergenerational inheritance of phenotypic traits via the 343 
female but not the male lineage in mice. However, the epigenetic mechanisms involved in 344 
determining the F2 placental phenotype still remain to be established.   345 
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TABLES 
Table 1 F1 offspring postnatal growth 
F1 weight (g) 
F0 treatment 
Control Dex D11-15 Dex D14-18 
Neonates n=33 n=34 n=36 
     Birth * 1.30 ± 0.03
a 
1.27 ± 0.01
ab 
1.19 ± 0.03
b 
Males n=7 n=9 n=14 
     3 weeks* 9.46 ± 0.24
a 
7.97 ± 0.30
b 
9.02 ± 0.22
a 
     6 weeks* 21.8 ± 0.4
ab 
20.2 ± 0.7
a 
22.2 ± 0.5
b 
     FGR 0-3 weeks (g g
-1
week
-1
)* 2.09 ± 0.08
ab
 1.79 ± 0.07
a
 2.19 ± 0.07
b
 
     FGR 3-6 weeks (g g
-1
week
-1
)* 0.43 ± 0.02 0.50 ± 0.02 0.50 ± 0.02 
Females n=7 n=5 n=5 
     3 weeks* 9.33 ± 0.32
a 
7.79 ± 0.47
b 
9.02 ± 0.22
ab 
     6 weeks* 18.8 ± 0.5
 
17.5 ± 0.2
 
17.4 ± 0.3
 
     FGR 0-3 weeks (g g
-1
week
-1
) 2.08 ± 0.14 1.75 ± 0.12 2.05 ± 0.12 
     FGR 3-6 weeks (g g
-1
week
-1
) 0.33 ± 0.02 0.41 ± 0.02 0.35 ± 0.02 
Mean (±SEM) body weight of F1 offspring of F0 dams either untreated (control) or treated with dexamethasone (dex) from days (D) 11-15 or  
D14-18 of pregnancy. FGR, Fractional growth rate = (final weight - initial weight)/(initial weight × 3 weeks). * indicates significant effect of F0 
treatment by one-way ANOVA (P<0.05). Values within rows with different superscripts are significantly different from each other by 
Bonferroni post-hoc test.  
Table 2 Biometry of pregnant F1 offspring and F2 conceptuses 
Weight 
F0 treatment 
Control Dex D11-15 Dex D14-18 
F1 male x untreated female n=9 litters n=13 litters n=18 litters 
Maternal weight (g) 38.6 ± 0.6 36.1 ± 0.8 35.4 ± 1.2 
     Carcass 25.6 ± 0.3  24.2 ± 0.5  23.5 ± 0.6  
     Gravid Uterus 13.1 ± 0.7  11.9 ± 0.5  11.8 ± 0.7  
F2 fetus (mg) 1207 ± 17 1204 ± 20 1220 ± 15 
F2 placenta (mg)  87 ± 6 86 ± 2 84 ± 1 
     Junctional zone 22 ± 3 21 ± 2 23 ± 3 
     Labyrinthine zone 47 ± 4 49 ± 1 43 ± 4 
Litter size (pups) 7.7 ± 0.5 7.1 ± 0.5 7.0 ± 0.3 
 
   
F1 female x untreated male n=5 litters n=5 litters n=6 litters 
Maternal weight (g)* 37.9 ± 1.0
a
 33.6 ± 0.9
b 
35.5 ± 1.0
 ab
 
     Carcass 24.2 ± 0.9 23.4 ± 0.4 22.8 ± 1.4  
     Gravid Uterus* 13.7 ± 0.5
a
 10.2 ± 0.9
b
 12.6 ± 0.6
a
 
F2 fetus (mg) 1125 ± 21 1097 ± 14 1135 ± 38 
F2 placenta (mg) 88 ± 5 84 ± 2
 
 85 ± 3 
     Junctional zone 24 ± 3 26 ± 2 25 ± 4 
     Labyrinthine zone 54 ± 5 46 ± 3 48 ± 2 
Litter size (pups) 7.8 ± 0.6 6.4 ± 0.8 7.5 ± 0.2 
Mean (±SEM) weights of pregnant mothers, fetuses and placentae on D19 of pregnancy in untreated females mated to F1 male offspring or F1 
female offspring mated to untreated males where F1 offspring was either untreated (control) or treated with dexamethasone (DEX) from days 
(D) 11-15 or D14-18 of the F0 pregnancy * indicates significant effect of F0 treatment by one-way ANOVA (P<0.05). Values within rows with 
different superscripts are significantly different from each other by Bonferroni post-hoc test.  
  
Figure 1 
Main figure, mean (±SEM) increments in blood glucose concentrations from baseline (0min) 
values in response to glucose administration at 0 minutes in adult F1 males of F0 dams that 
were untreated (Controls, open symbols) or treated with dexamethasone (Dex) at days (D) 
11-15 (black symbols) or D14-18 (grey symbols). The effects of time and maternal treatment 
were determined by two-way ANOVA (treatment P=0.0436, time P<0.0001, interaction 
P<0.0001), different letters a and b indicate different treament groups at each time point by 
Bonferroni post test. Inset, mean (±SEM) area under the curve of blood glucose concentration 
increment with time from glucose administration in adult F1 males as above. There was no 
significant effect of maternal treatment by one-way ANOVA. F1 n values: Control n=7, dex 
D11-15 n=9, dex D14-18 n=14 
 
Figure 2 
Mean (±SEM) values of materno-fetal MeAIB clearance across F2 placentae (A and C) and 
of placental Slc38a gene expression (B and D) in offspring of F1 fathers (A and B) and F1 
mothers (C and D) that were either untreated (controls) or exposed prenatally to 
dexamethasone (Dex) at days (D) 11-14 or D14-18 of the F0 pregnancy. The effect of F1 
prenatal treatment was determined by one-way ANOVA, different letters a and b indicate  
significantly different values by Bonferroni post-hoc test. (A), Control n=9, dex D11-15 
n=13, dex D14-18 n=17. (C), Control n=4, dex D11-15 n=4, dex D14-18, n=6. (B and D) n=5 
per treatment group.  
 
 
